A case of neuroendocrine neoplasm of the minor duodenal papilla

Aoyama, Naoki; Wada, Masaya; Taniguchi, Yoshinori; Inokuma, Tetsuro; Nakanishi, Yuki; Fukuda, Akira; Seno, Hiroshi

doi:10.1007/s12328-022-01739-w

Cited by 3 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, a 61yr old female in Japan was found to have a 15mm nodule at the descending duodenum confirmed as NET after endoscopic biopsy. Serum testing was normal and the lesion was classified as nonfunctional; the patient underwent subtotal stomach-preserving pancreaticoduodenectomy with good results [3]. In China, NET was reported in a 55yr-old female with a palpable non-tender upper abdominal mass.…”

Section: Discussionmentioning

confidence: 99%

Neuroendocrine Tumor Chromogranin A Response following Synthetic Somatostatin analog (Lanreotide): First Observations from an Isolated Duodenal Neoplasm

Sills¹,

Wood²,

Tan³

et al. 2023

Preprint

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) of duodenal origin are an unusual subset among all NETs, comprising only about 3% of this neoplasm class. In general, NETs are characterized by overexpression of somatostatin receptors and carry an excellent prognosis with early diagnosis and intervention. Chromogranin A (CgA), a protein originating in secretory vesicles of neurons and endocrine cells, has gained wide usage in NET diagnosis and surveillance. Lanreotide is a synthetic octapeptide somatostatin analog with potent anti-proliferative action which has been approved by the FDA (U.S.) and EMA (E.U.) for NET treatment. It is known for its inhibitory effects on growth hormone, serotonin, CgA, and other markers. Here we describe a 56yr-old female with functional NET of duodenal origin, where serum CgA was successfully reduced from 3636 to <100 ng/mL after multidose lanreotide within five months. Of note, no metastatic spread was identified on positron emission tomography/computed tomography with 64Cu-labeled somatostatin analog tracer. Surgical resection of distal antrum, pylorus, and proximal duodenum followed without complication. Histology revealed several foci of well-differentiated tumor cells with characteristic neuroendocrine features and clear surgical margins; low proliferation index (2%) was noted on Ki-67 staining. While select laboratory and imaging modalities are available for diagnosis and monitoring of duodenal NET, this is the first reported therapeutic use of lanreotide in this NET setting. The observed serum CgA attenuation, even before surgery, supports its effectiveness in management of primary nonmetastatic duodenal NET.

show abstract

Section: Discussionmentioning

confidence: 99%

Neuroendocrine Tumor Chromogranin A Response following Synthetic Somatostatin analog (Lanreotide): First Observations from an Isolated Duodenal Neoplasm

Sills¹,

Wood²,

Tan³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Neuroendocrine tumor of the minor duodenal papilla with lymph node metastasis: a case report and literature review

et al. 2023

View full text Add to dashboard Cite

Primary coexisting adenocarcinoma of the colon and neuroendocrine tumor of the duodenum: A case report and review of the literature

Fei,

Wu,

Zhang

et al. 2024

World J Gastrointest Surg

View full text Add to dashboard Cite

BACKGROUND Neuroendocrine tumors (NETs) arise from the body’s diffuse endocrine system. Coexisting primary adenocarcinoma of the colon and NETs of the duodenum (D-NETs) is a rare occurrence in clinical practice. The classification and treatment criteria for D-NETs combined with a second primary cancer have not yet been determined. CASE SUMMARY We report the details of a case involving female patient with coexisting primary adenocarcinoma of the colon and a D-NET diagnosed by imaging and surgical specimens. The tumors were treated by surgery and four courses of chemotherapy. The patient achieved a favorable clinical prognosis. CONCLUSION Coexisting primary adenocarcinoma of the colon and D-NET were diagnosed by imaging, laboratory indicators, and surgical specimens. Surgical resection combined with chemotherapy was a safe, clinically effective, and cost-effective treatment.

show abstract

A case of neuroendocrine neoplasm of the minor duodenal papilla

Cited by 3 publications

References 35 publications

Neuroendocrine Tumor Chromogranin A Response following Synthetic Somatostatin analog (Lanreotide): First Observations from an Isolated Duodenal Neoplasm

Neuroendocrine Tumor Chromogranin A Response following Synthetic Somatostatin analog (Lanreotide): First Observations from an Isolated Duodenal Neoplasm

Neuroendocrine tumor of the minor duodenal papilla with lymph node metastasis: a case report and literature review

Primary coexisting adenocarcinoma of the colon and neuroendocrine tumor of the duodenum: A case report and review of the literature

Contact Info

Product

Resources

About